Menu Back to 06

Track 6: Preclinical Development and Early-Phase Clinical Research

DIA 2017: Driving Insights to Action

Preclinical and early-phase clinical research provide initial safety, tolerability, and efficacy data for new drugs. This track focuses on topics ranging from early-stage compound selection, PK, and safety considerations for both drugs and biologics, as well as dosing strategies to data integrity for proper downstream decision-making.

Sessions in Preclinical Development and Early-Phase Clinical Research

Sunday, June 23 | Short Courses

View All Short Courses

Monday, June 24

Tuesday, June 25

Wednesday, June 26

Thursday, June 27

Watch one of our video interviews from DIA 2018 with DIA Global Chief Executive Barbara Lopez Kunz as she discusses FDA's modernization plan and its impact on developing innovative therapies with Nancy Myers, President and Founder, Catalyst Healthcare Consulting.

Who is This Track Designed For?

Professionals involved in: pharmacology and toxicology, nonclinical safety testing, clinical research, clinical operations, safety and pharmacovigilance, project management, patient centricity, and statistics; formulation science, pharmacokinetics/pharmacodynamics, epidemiology, toxicology, and regulatory affairs.

View Other Tracks


Registration Rates

Back to DIA 2019

Back to DIAglobal.org